<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152680</url>
  </required_header>
  <id_info>
    <org_study_id>NAV-17A-006</org_study_id>
    <nct_id>NCT05152680</nct_id>
  </id_info>
  <brief_title>Mass Balance Study of NV-5138 in Healthy Male Subjects.</brief_title>
  <official_title>An Open-label, Single Dose, Mass Balance Study to Assess the Disposition of [14C]-NV-5138 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navitor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Navitor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the mass balance and routes of excretion of total&#xD;
      radioactivity after a single oral dose of 1600 mg [14C]-NV-5138.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">December 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative total radioactivity in urine and faeces</measure>
    <time_frame>urine and fecal samples up to 168 hours post dose</time_frame>
    <description>The percentage of the radioactive dose recovered in urine, faeces and in total</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf for NV-5138, metabolite M8 and total radioactivity in plasma whole blood</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero (pre-dose) to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast for NV-5138, metabolite M8 and total radioactivity in plasma whole blood</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for NV-5138, metabolite M8 and total radioactivity in plasma whole blood</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for NV-5138, metabolite M8 and total radioactivity in plasma whole blood</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Time of maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast for NV-5138, metabolite M8 and total radioactivity in plasma whole blood</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Time of the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for NV-5138 and total radioactivity in plasma and whole blood</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for NV-5138 in plasma</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Total oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F for NV-5138 in plasma</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR Cmax in plasma</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>metabolite to parent ration based on Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR AUCinf in plasma</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>metabolite to parent ration based on AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood to plasma partitioning for total radioactivity</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>The AUCinf ratio of whole blood to plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR for NV-5138</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>Renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae for total radioactivity in urine and feces</measure>
    <time_frame>up to 168 hours post-dose</time_frame>
    <description>amount of total radioactivity excreted over each sampling period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Dose for total radioactivity in urine and feces</measure>
    <time_frame>up to 168 hours post-dose or until mass balance criteria have been met</time_frame>
    <description>amount of total radioactivity eliminated in faeces expressed as a percentage of the radioactive dose administered over each sampling period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>through study completion at one week</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]-NV-5138</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-NV-5138 oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-NV-5138</intervention_name>
    <description>Single dose, given as oral solution, 1600 mg</description>
    <arm_group_label>[14C]-NV-5138</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males aged 40 to 65 years inclusive at the time of signing informed consent.&#xD;
&#xD;
          -  Body mass index of 18.0 to 32.0 kg/m2 as measured at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Subjects who are, or are immediate family members of, a study site or sponsor employee&#xD;
&#xD;
          -  Evidence of current SARS-CoV-2 infection&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Regular alcohol consumption of &gt;21 units per week and (1 unit = Â½ pint beer, or a 25&#xD;
             mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)&#xD;
&#xD;
          -  A confirmed positive alcohol breath test at screening or admission&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission&#xD;
&#xD;
          -  Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          -  Subjects with pregnant or lactating partners&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker&#xD;
             shall participate in the study&#xD;
&#xD;
          -  Subjects who have participated in an ADME study involving carbon-14 within 12 months&#xD;
             of screening.&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, haematology or urinalysis as&#xD;
             judged by the investigator. Subjects with Gilbert's Syndrome are not allowed&#xD;
&#xD;
          -  Clinically significant abnormalities on vital signs or ECGs as judged by the&#xD;
             investigator at screening or pre-dose&#xD;
&#xD;
          -  Confirmed positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) antibody results&#xD;
&#xD;
          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance (CLcr) of &lt;80 mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, dermatological,&#xD;
             chronic respiratory or gastrointestinal disease or neurological disorder, as judged by&#xD;
             the investigator&#xD;
&#xD;
          -  Any history of major depression disorder (MDD) requiring treatment or counselling or&#xD;
             any other clinically significant psychiatric history, as judged by the investigator&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active&#xD;
&#xD;
          -  Donation of blood or plasma within the previous 3 months or loss of greater than 400&#xD;
             mL of blood&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug or&#xD;
             herbal remedies (other than up to 4 g of paracetamol per day) in the 14 days or 5&#xD;
             half-lives, whichever is longer, before IMP administration. COVID-19 vaccines are&#xD;
             accepted concomitant medications. Exceptions may apply on a case by case basis, if&#xD;
             considered not to interfere with the objectives of the study, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; Items 1 or 2 on the C-SSRS at screening&#xD;
&#xD;
          -  Failure to satisfy the investigator of fitness to participate for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG116JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Leafe</last_name>
      <phone>00159749000</phone>
      <email>kaitlyn.leafe@quotientsciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

